Zakrzewski Joseph S

Director Zakrzewski buys 2,000 ANTX shares at $1.40; stock down 93.6% from 52-week high of $21.53 amid cluster buying pattern

Joseph S Zakrzewski, a director at AN2 Therapeutics, purchased 2,000 shares at $1.40 on 2024-11-27, bringing his total holdings to 125,199 shares. This transaction is part of a cluster pattern, with 2 other insiders buying within the same 14-day window. The stock is severely depressed, trading at $1.37 versus a 52-week high of $21.53 (-93.6%), though it has recovered 24.6% over the past 30 days from lows. The company is unprofitable with negative net income of $12,747,000.00 over its most recent full fiscal year, and the market cap of $40,934,079.30 suggests a distressed biotech name. Zakrzewski's prior sale at this ticker on 2024-01-18 was well-timed by the 90-day mark (-87.0% return), but the fundamental weakness combined with extreme valuation collapse warrants scrutiny of whether this buy reflects contrarian conviction or routine rebalancing in a financially struggling entity.

Director Zakrzewski purchases 25,000 shares at $1.00–$1.01 as stock trades -94.0% from 52-week high; cluster buy pattern with 2 other insiders in 14 days

Zakrzewski Joseph S, Director at AN2 Therapeutics, executed 2 purchases totaling 25,000 shares for $25,046.00 on 2024-11-18 and 2024-11-19, raising his holdings from 98,199 to 123,199 shares (+25.5%). The purchases occurred at $1.00–$1.01 while the stock currently trades at $1.30, down -94.0% from its 52-week high of $21.53. The company reported a net loss of $-12,747,000.00 over its most recent full fiscal year. Additionally, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern. His prior open-market sell at this ticker in January 2024 was well-timed (90-day return -87.0%), though that historical pattern does not necessarily predict the outcome of this current purchase in a company with significant operating losses.